Evidence map›Paper›PMID 31531696›Full record

ArticleCancer immunology, immunotherapy : CII2019

Induction of tumor-specific CD8

Yuji Tomita, Eri Watanabe, Masumi Shimizu, Yasuyuki Negishi, Yukihiro Kondo, Hidemi Takahashi

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yuji TomitaDepartment of Microbiology and Immunology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8602, Japan.
Eri WatanabeDepartment of Microbiology and Immunology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8602, Japan.
Masumi ShimizuDepartment of Microbiology and Immunology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8602, Japan.
Yasuyuki NegishiDepartment of Microbiology and Immunology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8602, Japan.
Yukihiro KondoDepartment of Urology, Nippon Medical School, Tokyo, Japan.
Hidemi TakahashiDepartment of Microbiology and Immunology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8602, Japan. htkuhkai@nms.ac.jp.ORCID http://orcid.org/0000-0003-3283-0845
Nippon Medical School · JP

Funding

Grants from the Ministry of Education, Science, Sport, and Culture, from the Ministry of Health and Labor and Welfare, Japan 16K09262Grants from the Ministry of Education, Science, Sport, and Culture, from the Ministry of Health and Labor and Welfare, Japan 25461715
6 · The paper itself

Abstract

The main effectors in tumor control are the class I MHC molecule-restricted CD8

Indexed as

Antigens, SurfaceCell Line, TumorDendritic CellsHumansInterleukin-12LipopolysaccharidesMycobacteriumMycobacterium bovisMycolic AcidsNeoplasmsThrombomodulinT-Lymphocytes, CytotoxicAntigens, SurfaceInterleukin-12lipoarabinomannanLipopolysaccharidesMycolic AcidsTHBD protein, humanThrombomodulinBCGCTLsDCsLipoarabinomannanMycobacterium tuberculosisMycolic acid

Identifiers

PMID31531696
PMCPMC6805962
OpenAlexW2973863415

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.